ClinicalTrials.gg
CompletedNCT05567757Updated Jul 3, 2025

Initial Safety Study of the TRUE AVC in Hemodialysis Access (TRUE AVC I Study)

A Phase 1/2 interventional study of Arteriovenous conduit implant in End Stage Renal Disease, sponsored by Vascudyne, Inc.. Completed at 1 site in Panama. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Vascudyne, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Study summary

Prospective, nonrandomized, single-arm, single-center, open-label, initial safety study in subjects requiring hemodialysis. Subjects will be followed with physical evaluation and ultrasound vessel imaging at days 15, 29, 57 and weeks 12, 26. Extended follow up on patent conduits only at weeks 52 and 104.

Read the detailed description

Twenty (20) patients with end-stage kidney disease (ESKD), who are poor candidates for an autogenous fistula creation and either on hemodialysis or expected to start hemodialysis within 12 weeks of study conduit implantation will be implanted with a TRUE AVC as an arteriovenous conduit in the upper extremity. Study subjects will be evaluated for implant safety and patency at 26 weeks. Subjects will be followed with physical evaluation and ultrasound vessel imaging at days 15, 29, 57 and weeks 12, 26. Extended follow up on patent conduits only at weeks 52 and 104.

02

Conditions studied

  • End Stage Renal Disease

Keywords

  • hemodialysis
  • arteriovenous access
03

In context

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's enrollment of 11 is below the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Vascudyne, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with end stage kidney disease (ESKD) who are poor candidates for creation of a simple autogenous AV fistula (without requiring transposition) and therefore need placement of an AV access in the upper extremity to start or maintain hemodialysis therapy.
  2. Either on hemodialysis or expected to start hemodialysis within 12 weeks of study conduit implantation.
  3. Patients between 18 and 75 years old, inclusive.
  4. Verify adequate arterial flow and venous runoff using duplex ultrasound and venogram. Ensure outflow vein is at least 5 mm in diameter with good compliance.
  5. ≥8g/dL and count ≥100,000/mm3 prior to implant.
  6. Other hematological and biochemical parameters within a range consistent with ESKD and acceptable for the administration of regional or general anesthesia prior to implant.
  7. Adequate liver function, defined as serum ≤1.5 mg/dL; GGT, , ALT, and alkaline phosphatase ≤2x or ≤ 1.5 prior to implant.
  8. of at least 1 year.
  9. Negative COVID-19 test within 3 days prior and negative for symptoms within 14 days prior to implant.
  10. Female subjects must be either:

    1. Of non-, which is defined as (at least 1 year without menses prior to Screening) or documented surgically sterile or post hysterectomy (at least 1 month prior to Screening)
    2. Or, of childbearing potential, in which case:

    i. Must have a negative urine blood pregnancy test at Screening, and ii. Must agree to use at least one form of the following methods for the duration of the study:

1. Established use of oral, injectable or implanted hormonal methods of contraception 2. Placement of an intrauterine device or intrauterine system 3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/ gel/ film/ cream/ suppository 11. Able to communicate meaningfully with investigative staff and able to comply with entire study procedures.

12. Willing and competent to give written

Exclusion criteria

Exclusion Criteria:

  1. History or evidence of severe cardiac disease ( Functional Class III or IV); myocardial infarction within six months prior to study entry; ventricular tachyarrhythmias requiring continuing treatment; unstable angina; or \< 50%.
  2. Uncontrolled or poorly controlled diabetes defined as > 8; hospitalization for poor glucose control within the previous 6 months.
  3. History or evidence of severe peripheral vascular disease in the upper limbs
  4. Known or suspected central vein obstruction on the side of planned study conduit implantation. Avoid patients with current subclavian catheters or leads on the side of the study conduit implant. If the patient had previous subclavian catheters or leads on the implant side, verify adequate runoff with a venogram.
  5. Documented hypercoagulable state or history of thromboembolic events or history of repeated venous catheter clotting.
  6. Known Positive COVID 19 test result or known exposure to COVID 19 in past 3 months.
  7. Known active infection including dental infection, osteomyelitis and other conditions which could present a local or systemic risk of infection.
  8. Bleeding diathesis.
  9. to or known serious allergy to anticoagulant, aspirin, or planned antiplatelet therapy. History of heparin-induced thrombocytopenia.
  10. Immunodeficiency including AIDS / or active disease, or on therapy.
  11. Autoimmune nephropathy
  12. Previous PTFE graft in the operative limb unless the TRUE AVC can be placed more proximally than the previous failed graft.
  13. More than 1 failed PTFE graft in the operative limb.
  14. Patients receiving an AV access which crosses the elbow.
  15. Patients receiving a lower extremity AV access.
  16. Treatment with any drug or device within 60 days prior to study entry or ongoing participation in a clinical trial of an investigational product.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Investigational

    Study subjects implanted with a TRUE AVC as an arteriovenous conduit for hemodialysis

    Biological: Arteriovenous conduit implant

Interventions

  • BiologicalArteriovenous conduit implant

    Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity

06

What researchers measure

Primary outcomes

  1. Adverse Event Incidence

    incidence of clinically significant aneurysm, anastomotic bleeding, study conduit or anastomotic rupture, study conduit infection, and implant site irritation, inflammation, or infection

    Time frame: through 26 weeks post implant

  2. Patency

    Kaplan-Meier freedom from loss of primary patency, primary assisted patency, and secondary patency.

    Time frame: through 26 weeks post implant

Secondary outcomes

  1. Change in antigen sensitivity

    Assess changes in anti-HLA sensitivity in each implant recipient, from baseline through four weeks, using panel reactive antibody (PRA) test

    Time frame: baseline through 4 weeks

  2. Rate of Interventions

    Rate of interventions needed to maintain patency

    Time frame: 26 weeks

07

Study locations

1 site
  • Centro de Asistencia Renal
    Río Hato, Provincia de Coclé, Panama
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Mar 2025, 29 months.

Of 29 phase 1/2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 5, 2022
StartActual
Oct 4, 2022
Primary completionActual
Mar 30, 2025
CompletionActual
Mar 30, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05567757
Lead sponsor
Vascudyne, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Oct 4, 2022
Primary completion
Mar 30, 2025
Completion
Mar 30, 2025
Last update
Jul 3, 2025

Study contacts

Ernesto Alvarado, MD
principal investigator · Centro de Asistencia Renal, Río Hato, Coclé, Panamá

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion